Final analysis results from a multicenter clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy in patients with cT2-T4aN0M0 MIBC.

Authors

null

Tianxin Lin

Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

Tianxin Lin , Kaiwen Li , Jinhai Fan , Shaogang Wang , Dexin Yu , Tao Xu , Jiaju Lyu , Tao Qin , Zheng Liu , Kaijie Wu , Jinyou Wang , Qi Wang , Jie Min , Zhiquan Hu , Fan Li , Zhiqiang Zhang , Luping Yu , Sentai Ding , Jian Huang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Local-Regional Disease

Clinical Trial Registration Number

ChiCTR2000037670

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4585)

DOI

10.1200/JCO.2023.41.16_suppl.4585

Abstract #

4585

Poster Bd #

77

Abstract Disclosures